Year: 2024

– Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this weekend in oral and poster presentations at ACR Convergence 2024 – – 16 patients enrolled with 10 patients dosed as of November 12 across the RESET™ clinical development program; 40 U.S. clinical sites actively recruiting patients – – Data permitting, anticipate meeting with the FDA in 2025 regarding potential registrational program designs for CABA-201 – – Clinical development expanding efficiently into Europe with EMA CTA authorization for CABA-201 received in lupus; Gerwin Winter appointed as Senior VP and Head of International – – Cash, cash equivalents and short-term investments total $183.0 million as of September 30, 2024, expected to support operations into...

Earnings Release HighlightsGAAP Net Income (Loss) Attributable to Stockholders of $168 million for the third quarter 2024 and $916 million year-to-date. Adjusted EBITDA of $230 million and Adjusted Free Cash Flow of $97 million for the third quarter 2024; year-to-date Adjusted EBITDA of $606 million and Adjusted Free Cash Flow of $262 million. Raising and narrowing 2024 guidance ranges: Adjusted EBITDA of $750 to $780 million and Adjusted Free Cash Flow of $265 to $285 million. Reaffirming 2025 guidance ranges: Adjusted EBITDA of $925 to $1,175 million and Adjusted Free Cash Flow of $395 to $595 million. Became the 100% owner of the Nautilus JV by completing the strategic purchase of TeraWulf’s remaining equity interest in Nautilus. Repurchased approximately 2.6 million shares of stock at an average price of $117.64 per share during...

OTTAWA, Ontario, Nov. 14, 2024 (GLOBE NEWSWIRE) — Telesat (NASDAQ and TSX: TSAT), one of the world’s largest and most innovative satellite operators, today announced its financial results for the three and nine-month periods ended September 30, 2024. All amounts are in Canadian dollars and reported under International Financial Reporting Standards (IFRS) unless otherwise noted. “The third quarter showed strong progress in our build-out of Telesat Lightspeed, our state-of-the-art Low Earth Orbit (LEO) constellation,” commented Dan Goldberg, Telesat’s President and CEO. “During the quarter, we concluded our funding arrangements with the governments of Canada and Quebec, securing the financial resources necessary to fund the global Telesat Lightspeed network. Telesat Lightspeed will revolutionize broadband connectivity for enterprise...

Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s dementia Conference call set for 8:00 a.m. ET today NEW HAVEN, Conn., Nov. 14, 2024 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced its financial results for the third quarter of 2024. “Our focus continues to be the clinical development of BXCL501,” said Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics. “We are advancing our SERENITY At-Home trial to pursue the near-term growth opportunity for treating acute agitation associated with bipolar disorders or schizophrenia in the outpatient setting. At the same time, we are progressing with our TRANQUILITY...

MISSISSAUGA, Ontario, Nov. 14, 2024 (GLOBE NEWSWIRE) — Next Hydrogen Solutions Inc. (the “Company” or “Next Hydrogen”) (TSXV:NXH, OTC:NXHSF), a designer and manufacturer of electrolyzers, is pleased to report its financial results for the third quarter ended September 30, 2024. “Next Hydrogen delivered its second-generation system to a customer following an extended factory acceptance test. Further, it passed a key cell performance durability test for this product line which positions us well to deliver on our five demonstrations in 2025,” said Raveel Afzaal, President & CEO. “Next Hydrogen is focused on strengthening its balance sheet to deliver on its growing backlog through (1) $3M of convertible debt offering, (2) $4.6M of approved government grants with an additional $2M in advanced discussions, and (3) on-going discussions...

– Company to Host Webcast and Conference Call – BRANFORD, Conn., Nov. 14, 2024 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH), a real estate lender specializing in originating, underwriting, funding, servicing, and managing a portfolio of loans secured by first mortgages on real property, today announced its financial results for the third quarter ended September 30, 2024. “While origination activity remains muted, we continue to see significant proprietary deal flow, as traditional banks remain on the sidelines,” said John Villano, CPA, Sachem Capital’s Chief Executive Officer. “During the quarter, we maintained discipline with short-term debt coming due, but executed several strategic initiatives, including diversifying our business model with an additional investment in Shem Creek...

Strategic transformation produced record quarterly total revenue of $38.6 million, with earnings increasing to $0.05 per diluted share for the third quarter of 2024 Adjusted EBITDA increased 45% year-over-year to a quarterly record of $12.2 million BOCA RATON, Fla., Nov. 14, 2024 (GLOBE NEWSWIRE) — FlexShopper, Inc. (Nasdaq: FPAY) (“FlexShopper”), a leading national online lease-to-own (“LTO”) retailer and payment solution provider for underserved consumers, today announced its financial results for the quarter ended September 30, 2024. Russ Heiser, Jr, Chief Executive Officer, stated, “2024 is shaping up to be a transformative year for FlexShopper as the strategies we are pursuing to profitably grow our business take hold and more retail partners and consumers recognize the value of our unique payment solutions. We are successfully...

BROOKFIELD, NEWS, Nov. 14, 2024 (GLOBE NEWSWIRE) — Brookfield Wealth Solutions (NYSE, TSX: BNT) today announced financial results for the quarter ended September 30, 2024. Sachin Shah, CEO, stated, “We generated strong returns in the quarter, led by $5 billion of investment redeployment at accretive risk-adjusted yields. Our investment capabilities combined with our strong retail annuities platform position us well for future growth.”UnauditedAs of and for the periods ended September 30(US$ millions, except per share amounts)Three Months Ended   Nine Months Ended  2024     2023     2024     2023Total assets $ 137,112   $ 51,177   $ 137,112   $ 51,177Adjusted equity1   11,434     7,251     11,434     7,251Distributable operating earnings1   370     182     947     487Net income   65     77     671     344Net...

LITTLE ROCK, Ark., Nov. 14, 2024 (GLOBE NEWSWIRE) — Dillard’s, Inc. (NYSE: DDS) (the “Company” or “Dillard’s”) announced operating results for the 13 and 39 weeks ended November 2, 2024. This release contains certain forward-looking statements. Please refer to the Company’s cautionary statements included below under “Forward-Looking Information.” Dillard’s Chief Executive Officer William T. Dillard, II stated, “While retail sales declined 4%, we focused on gross margin, reporting a respectable 44.5% of sales, while working on expense control. We reported cash and short-term investments of over $1.1 billion after repurchasing $107 million in stock. We are looking forward to welcoming our customers and serving them this holiday season.” Highlights of the Third Quarter (compared to the prior year third quarter):Total retail sales...